Sigma Of Australia Battle Over Effexor Eyed Closely By Others
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceutical and its attempts to break loose of Wyeth's Effexor (venlafaxine) antidepressant are being watched closely by other generics makers as Sigma wages its patent battles. Effexor is the best-selling antidepressant in Australia and Sigma has lost its first court challenge to break the patent. Sigma faces two other patents Wyeth claims for the drug. Other generics makers seek to market the drug in Australia where the national health plan shelled out about $80.7 million for it last year. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.